Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. (Q39122499)
Jump to navigation
Jump to search
scientific article published on 19 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. |
scientific article published on 19 July 2013 |
Statements
1 reference
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. (English)
1 reference
Ivana Yen
1 reference
Shiva Malek
1 reference
Elizabeth Blackwood
1 reference
Jennifer Epler
1 reference
Michael Flagella
1 reference
Tom O'Brien
1 reference
Marie Evangelista
1 reference
Stephen Schmidt
1 reference
Yang Xiao
1 reference
Jonathan Choi
1 reference
Kaska Kowanetz
1 reference
Judi Ramiscal
1 reference
Kenton Wong
1 reference
Diana Jakubiak
1 reference
Sharon Yee
1 reference
Gary Cain
1 reference
Lewis Gazzard
1 reference
Karen Williams
1 reference
Jason Halladay
1 reference
Peter K Jackson
1 reference
19 July 2013
1 reference
1 reference
Identifiers
1 reference